![Michael Cassano](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historique de carrière de Michael Cassano
Anciens postes connus de Michael Cassano
Sociétés | Poste | Début | Fin |
---|---|---|---|
Orasi Medical, Inc.
![]() Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Directeur Technique/Scientifique/R&D | 20/04/2009 | 18/08/2012 |
JOHN WILEY & SONS, INC. | Corporate Officer/Principal | - | - |
Formation de Michael Cassano
University of Minnesota | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 4 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectorielle
Consumer Services | 3 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
JOHN WILEY & SONS, INC. | Consumer Services |
Entreprise privées | 1 |
---|---|
Orasi Medical, Inc.
![]() Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Health Services |
- Bourse
- Insiders
- Michael Cassano
- Expérience